Arrowhead Pharmaceuticals price to sales ratio ARWR
Market value divided by revenue over the last twelve months, since 2013.
- Today, Nov 2, 2026
- 12.6×
- 10-year median
- 21.0×
- Against its 10-year history
- 24th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 3.8× to 157×
- Peer median
- 6.5×
Arrowhead Pharmaceuticals' price to sales ratio is 12.6× as of Nov 2, 2026.
That is below its ten-year median of 21.0×, lower than on 76% of days in the last ten years.
Over that time it ranged from 3.8× in May 2025 to 157× in Aug 2024.
The median for 10 large drugmakers of a similar size is 6.5×.
Price to sales ratio over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 12.6× | 7.1× | 19.4× |
| 2025 | 11.5× | 3.8× | 11.5× |
| 2024 | 117× | 14.3× | 157× |
| 2023 | 13.7× | 9.5× | 16.3× |
| 2022 | 17.7× | 11.7× | 44.6× |
| 2021 | 50.1× | 50.1× | 118× |
| 2020 | 89.6× | 16.2× | 98.3× |
| 2019 | 36.8× | 18.8× | 85.0× |
| 2018 | 68.2× | 11.6× | 128× |
| 2017 | 8.8× | 6.1× | 37.0× |
| 2016 | n/m a value too high to mean anything | ||
| 2015 | n/m a value too high to mean anything | ||
| 2014 | n/m a value too high to mean anything | ||
| 2013 | 196× | 107× | 196× |
Against its peers
Companies in Drug Manufacturers - General nearest Arrowhead Pharmaceuticals' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| ARWRArrowhead Pharmaceuticals | 12.6× |
| CORTCorcept Therapeutics | 10.5× |
| PTGXProtagonist Therapeutics | 32.0× |
| TGTXTG Therapeutics | 11.5× |
| ALKSAlkermes plc. | 4.5× |
| KNSAKiniksa Pharmaceuticals International | 8.4× |
| AMRXAmneal Pharmaceuticals | 2.1× |
| BMRNBiomarin Pharmaceutical | 3.3× |
| LGNDLigand Pharmaceuticals | 21.1× |
| JAZZJazz Pharmaceuticals | 3.0× |
| INDVIndivior Pharmaceuticals | 3.1× |
| Peer median | 6.5× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Arrowhead Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.